Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 9Recurrence 2Brain Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Locally Advanced Melanoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Central Nervous System Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 12Radiotherapy 9avelumab 8Nivolumab 8cemiplimab 4Radiation 4Ipilimumab 4poly ICLC 3atezolizumab 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Etoposide 3Cyclophosphamide 3talimogene laherparepvec 2lutetium Lu 177 dotatate 2fludarabine phosphate 2fludarabine 2durvalumab 2aldesleukin 2Interferon-beta 2Immunoglobulin G 2Immune Checkpoint Inhibitors 2Cisplatin 2Carboplatin 2Biopsy 2veliparib 1vatalanib 1tremelimumab 1tocilizumab 1temsirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Merkel Cell × Opdualag × Clear all
NCT06151236 2026-02-17

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Melanoma Institute Australia

Phase 2 Recruiting
20 enrolled
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡